简体中文
English
Website review
This review may include AI-generated content and is not individually verified. Domain, certificate and other facts come from the observed data on this page.
What is DM365 MainEDC used for?
DM365 MainEDC is an eClinical platform for running clinical trials: it handles electronic data capture (EDC), patient-reported outcome collection (ePRO), randomization and trial supply management (IWRS), and risk-based monitoring (RBM). The site positions it as a single system for studies "of any complexity," aimed at pharma, biotech and CROs, with claims of fast study start-up (median first-patient-in around 9.2 days, as fast as 5) and support for audit and inspection questions. It also lists compliance with 21 CFR Part 11, GCP, GDPR and HIPAA, plus private cloud hosting.
Who it fits
- Biotech running its first or occasional trials: the site explicitly targets teams without frequent trial experience, offering templates and hands-on help.
- CROs: positioned around resource savings and producing documentation packages for regulators such as FDA and EMA.
- Sponsors needing ePRO or supply randomization: ePRO and IWRS are named modules, so patient diaries and randomization can sit in one platform rather than separate vendors.
Trade-offs to weigh
A single-vendor platform simplifies integration and training, but concentrates risk: if one module lags, everything connected to it does. A modular approach means more integration work but lets you pick best-in-class tools. Ask which modules are mature versus newly added, and whether data export to your statistical environment is straightforward.
Next step
Define your study's must-haves (ePRO? randomization? monitoring?) and ask for a demo scoped to those, plus references from a team of similar size. The vendor's own materials are at DM365 MainEDC; for independent context on eClinical selection, TransCelerate publishes shared practices.
How fast can I start a clinical trial with MainEDC compared to the industry average?
MainEDC's vendor, DM365, advertises a median first-patient-in (FPI) of about 9.2 days after study start, and says projects can launch in as few as 5 days. It contrasts this with an industry average study start of roughly 12.7 weeks (about 89 days). In other words, the claimed difference is on the order of weeks to a couple of months, not days.
What the numbers mean
- "FPI in 5–9 days" refers to the time from kicking off a study on the platform to enrolling the first patient, based on the vendor's own portfolio (including a cited "FPI in 2 days" case).
- "12.7 weeks" is presented as the typical industry start time, which usually includes site contracts, ethics/IRB approvals and database build. Those steps sit partly outside any EDC platform, so treat the comparison as marketing framing rather than a like-for-like benchmark.
A realistic way to judge it
If you are a small biotech or a CRO running a straightforward protocol, the practical question is how much of your start-up delay comes from database and eCRF build versus site and regulatory steps. MainEDC's pitch—ready-made templates, a visual edit-check builder and quick eCRF construction—targets the build portion, which is where a platform can genuinely compress timelines. For complex protocols or first-time sponsors, site activation and approvals may dominate regardless of the system.
As a next step, ask DM365 for references with timelines comparable to your study (same phase, regions and complexity), and map their claimed 5–9 days against your own site and ethics timeline before treating it as your expected start date. You can review the platform and request a trial via DM365: MainEDC.
Is MainEDC suitable for a small biotech running its first clinical trial?
Yes—MainEDC is positioned for exactly that situation. The vendor states it works with biotech teams "where teams have to deal with clinical trials for the first time or not so often," and offers to act as part of your team during launch. For a first-trial biotech, the practical appeal is less about feature depth and more about getting to First Patient In quickly with templates and data-management practices you don't yet have in-house.
What matters most for a first trial
- Speed to start: The site claims a median 9.2 days to FPI after project start, and as fast as 5 days in the best case. Treat these as vendor figures, but even a conservative reading suggests a shorter setup than building an EDC configuration from scratch.
- Breadth in one platform: EDC, ePRO, eCOA/ERT, RBM and a register are listed under one roof. For a small team, fewer vendors means fewer integrations and contracts to manage.
- Built-in guidance: "Transfer of Competence" is explicitly about sharing the vendor's data-management and data-science expertise through joint work on your project—useful if you have one overstretched data manager.
- Compliance posture: The site cites 21 CFR Part 11, GCP E6 R2, GDPR and HIPAA, plus private cloud hosting and support during audits and inspections. That audit support is often the real anxiety point for a first sponsor.
- Cost model: "Pay as you go" with a stated fixed, open price is friendlier to a single-study budget than enterprise licensing; the site also claims platform savings up to 80%, which you should verify against your own scope.
Trade-offs to weigh
A first trial usually means a simple protocol, a small site count and a tight budget. A broad platform can be more than you need, and the competence-transfer model works best when you have at least one internal person who can own data management decisions. Also confirm that ePRO fits your patient population—if the trial is site-heavy with paper-friendly endpoints, you may not need it in study one.
Practical next step
Ask for a demo scoped to your actual protocol, and request three things in writing: a fixed price for that single study, a sample timeline to FPI with named responsibilities, and references from biotechs of similar size. Compare that against a lean alternative such as Medrio or Castor, which are commonly chosen for smaller studies, and decide on total cost and internal effort rather than feature count.
How much can a CRO save on EDC, eCOA, and monitoring costs by switching to MainEDC?
MainEDC's own marketing puts the savings at up to 80% off on a combined EDC, ERT and eCOA platform and up to 75% off on clinical monitoring. Treat these as vendor claims rather than guaranteed figures, and note that the page says "ERT" where the question says "eCOA" — the two are often bundled, but confirm what is actually covered in a quote.
What the vendor claims vs. what to verify
| Claim on the page | What it likely reflects | What to check |
|---|---|---|
| Up to 80% off platform costs (EDC, ERT, eCOA) | Pay-as-you-go pricing and a single platform replacing several licensed tools | Which modules are in scope, per-study vs. per-subject fees, and setup or validation charges |
| Up to 75% off monitoring | Built-in edit-checks and visual eCRF builder reducing source-data review and query volume | Whether the saving comes from fewer monitoring visits or just cheaper tooling |
| Deploy studies in days (9.2-day median FPI; as fast as 5 days) | Templates and ready-made DM/DS practices | Whether your protocol's complexity fits those templates |
| Compliance: 21 CFR Part 11, GDPR, HIPAA, GCP E6 R2 | Private cloud hosting and validation support | Your own audit trail and validation documentation needs |
A realistic way to estimate your own savings
Build a baseline from your last two or three studies: platform licence and per-subject fees, eCOA/ePRO device and licence costs, monitoring visit days and travel, and data-management query resolution hours. Then apply the vendor's percentages only to the line items MainEDC actually replaces. For a mid-sized CRO running several studies a year, the platform line is usually the largest single lever; monitoring savings depend more on how much your current process relies on on-site source verification.
Who benefits most
- CROs running varied, frequent studies — the page explicitly targets CROs wanting an industry-standard package with documentation for FDA/EMA submissions.
- Biotech teams new to trials — the "Transfer of Competence" and mentoring services matter more than headline discounts when you lack in-house data-management staff.
- Large sponsors — the page cites 148 pharma, biotech and CRO customers and trials with 70,000+ subjects, useful as a scale reference.
Next step: request a quote scoped to one representative study and ask for the per-subject and per-module breakdown, so you can compare it against your current EDC, eCOA and monitoring spend line by line rather than against the headline percentages. See DM365: MainEDC for the platform and pricing pages.
What regulatory compliance and security standards does MainEDC meet for audits and inspections?
MainEDC is presented as meeting GCP E6 R2, GAMP 5, 21 CFR Part 11, GDPR and HIPAA requirements, with private cloud hosting described as its premium security level. The vendor also says it has extensive experience supporting audits and inspections and will help users answer auditor or inspector questions about the platform. These are the vendor's stated compliance positions; a sponsor should still obtain the validation documentation, audit-trail and e-signature evidence, hosting details and any recent inspection outcomes directly during vendor qualification.
What to verify before relying on these claims
- Validation package: GAMP 5 and 21 CFR Part 11 claims should come with a validation plan, IQ/OQ/PQ documentation and change-control records you can review.
- Audit trail and e-signatures: Confirm how audit trails are captured, reviewed and exported, and how electronic signatures are controlled.
- Data protection: Ask where data is hosted, how access is restricted and how GDPR and HIPAA obligations are handled under your contract.
- Inspection support: Clarify what "help answering auditor questions" means in practice—documentation, a named contact, or on-call support during an inspection.
For a concrete decision criterion, treat the compliance list as a starting point for due diligence, not as proof. A small biotech running its first trial may lean on the vendor's templates and inspection support; a CRO or larger sponsor will want to see the underlying validation evidence and hosting arrangements before committing.
As a next step, request the validation and security documentation alongside a demo, and compare it with other eClinical platforms such as Medidata or Veeva if you are evaluating multiple vendors.
How does MainEDC's AI-powered medical coding work and what does it automate?
MainEDC's page presents AI-based automated medical coding as part of its eClinical platform, describing it as "the first market solution based on AI for automated medical coding." The site does not explain the underlying mechanism—whether it maps free-text or verbatim terms to dictionaries such as MedDRA or WHO Drug, how suggestions are reviewed, or what accuracy checks exist. So the honest answer is: it automates the coding step of turning recorded medical terms into standardized codes, but the page gives no detail on how that automation is performed or verified.
What the page does and doesn't say
| Question | What the page states | What it leaves open |
|---|---|---|
| What is automated? | Medical coding, via AI | Which dictionaries, which coding levels, whether coding is fully automatic or suggestion-based |
| Who benefits? | Sponsors, CROs and biotech teams running trials of "any complexity" | Whether small first-time teams get the same benefit as high-volume coders |
| How is it verified? | General claims of audit and inspection experience and help answering auditor questions | No description of a review workflow, audit trail for code changes, or validation approach specific to the AI coding |
A practical way to judge it
For a data manager, the value of automated coding depends on the review step, not the automation itself. A realistic scenario: a mid-size study generates thousands of adverse-event terms and concomitant medications; auto-coding saves hours, but someone must still confirm codes, handle ambiguous terms, and keep a record of changes for inspection. Before relying on this feature, ask the vendor for a demonstration using your own messy verbatim terms, and ask specifically how coders review and override suggestions and how those decisions are logged.
For broader context on EDC and coding workflows, CDISC publishes the standards many coding and submission processes align to, and MedDRA is the official source for the terminology commonly used in adverse-event coding.
Google Workspace
User reviews (0)